Suven gets patents for neuro-degenerative drug

The Dollar Business Bureau

Suven Life Sciences (Suven) on Tuesday announced it has received approvals of one product patent each from India and South Africa. 

“One product patent from India and one product patent from South Africa corresponding to the New Chemical Entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases," the company said in an announcement.  

These two patents are valid through 2028 and 2032 respectively.

The granted patents include the class of 5-HT6 compounds and H3 inverse agonist compounds. There are being developed as therapeutic agents and will be used for the treatment of cognitive impairment related to neurodegenerative disorders such as Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, major depressive disorder (MDD), Parkinson and Schizophrenia.

With the grants of these new patents, the Hyderabad-based drug major has secured 18 granted patents from India. The company had got 23 granted patents from South Africa.

“These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II,” the company said.

Suven Life Sciences' net profit grew 90.5% to Rs 32.29 crore. Its net sales rose by 53% to Rs.169.28 crore in the fourth quarter of 2016 over the same period last year.